A public health approach to addressing and preventing misdiagnosis in the scale-up of HIV rapid testing programmes. by Johnson, Cheryl C et al.
Editorial
A public health approach to addressing and preventing
misdiagnosis in the scale-up of HIV rapid testing
programmes
Cheryl C. Johnson1,2§, Shona Dalal1, Rachel Baggaley1 and Miriam Taegtmeyer3
§Corresponding author: Cheryl C. Johnson, Department of HIV, World Health Organization, 20 Avenue Appia, Geneva, 1201, Switzerland. (Johnsonc@who.int)
Keywords: HIV; diagnostic; rapid diagnostic test; test; quality; misdiagnosis; misclassification
Received 26 June 2017; Accepted 03 July 2017; Published 29 August 2017
Copyright: © 2017 World Health Organization; licensee IAS. This is an open access article distributed under the terms of the Creative Commons Attribution IGO
License (http://creativecommons.org/licenses/by/3.0/igo/legalcode), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organisation or
products. The use of the WHO logo is not permitted.
Introduction
The global impact of the scale-up HIV testing and treatment has
been impressive. In 2015, approximately 60% of people with
HIV worldwide were aware of their status [1]. As a result by the
end of 2015, 17 million people with HIV were on treatment,
and global treatment coverage reached 46% [1]. HIV testing
and treatment have reduced AIDS-related deaths by 43% since
2003 [1,2]. In order to further increase impact and improve
health outcomes, in 2016 the World Health Organization
(WHO) recommended antiretroviral therapy (ART) for all peo-
ple with HIV regardless of disease status [3]. These calls to
continue scale-up of testing and treatment and to achieve the
United Nation’s (UN) “90-90-90” targets remain a global prior-
ity. Achieving the “first 90” by reaching people with HIV who
have yet to be diagnosed, and linking them to treatment as
early as possible, is a critical first step.
Degrees of uncertainty exist with all medical testing and
diagnoses; in the field of HIV, advances in diagnostic test
technology have made testing accurate and reliable. WHO
prequalified HIV rapid diagnostic tests all have a sensitivity
of ≥99% and specificity ≥98% and are accurate when used
correctly in a validated national algorithm. A large number of
tests are conducted every year. Although a degree of error
and misdiagnosis can be expected, very few cases of false
negative and false positive diagnoses have been reported [4–
12]. This lack of reporting on testing error and misdiagnoses is
not unique to HIV [13–16]. Publication bias and concerns
about programme reputation may have contributed to low
reporting of misdiagnosis and limit the open discussion
required to address errors systematically [16].
To further investigate diagnostic error, determine com-
mon causes, and identify potential ways to address mis-
diagnosis, particularly in resource-limited settings, WHO,
Liverpool School of Tropical Medicine and Médecins Sans
Frontières (MSF) held a symposium to address the social,
public health, human rights, ethical and legal implications
of misdiagnosis of HIV status [17]. This special issue of the
Journal of the International AIDS Society follows this sym-
posium by focusing on the individual and public health
implications of HIV misdiagnosis.
Is HIV misdiagnosis a “real” problem?
Data from a systematic review of 64 studies (most studies
identified were conducted in Africa and other resource-lim-
ited settings) are included in this special issue and summarize
the magnitude of misdiagnosis in these contexts. The review
suggests that on average 0.4% (interquartile range (IQR):
0–3.9%) of diagnoses primarily among adults are false nega-
tive and 3.1% (IQR: 0.4–5.2%) are false positive [18]. Among
people diagnosed with HIV who were enrolled in care and/or
on ART, between 0.1% and 6.6% of patients were reported to
be truly HIV negative and had been misdiagnosed [18]. The
diagnostic errors identified were largely related to human
error [18]. Although reported levels of misdiagnosis are low,
if current estimates are accurate [18,19], the large volume of
tests conducted each year - over 150 million tests in low- and
middle-income countries in 2014 alone, 3 million of which
were HIV positive [19] - could result in the misdiagnosis of up
to 93,000 people per year if left unaddressed.
What factors and processes contribute to
misdiagnosis using rapid tests?
HIV misdiagnoses and testing errors are unlikely to be the
result of a single cause or underlying factor. Diagnostic
errors can occur across multiple steps within the HIV testing
continuum, starting from national policy and training,
through the supply chain, initial testing and the delivery
of a diagnosis, including retesting patients prior to ART
initiation as well as inadvertently retesting patients on
ART who may re-present for testing erroneously (Figure 1).
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The review by Johnson et al. [18] highlighted that the
use of suboptimal testing algorithms was a common cause
of misdiagnoses in studies reviewed. In this issue, Bock
et al. report that by using a first-line assay with poor
sensitivity in South Africa, the resulting programmatic sen-
sitivity was as low as 45% (95% confidence interval:
23–48) [21]. Another known contributor to misdiagnosis
is the use of a tiebreaker test to rule in HIV infection after
discrepant test results, which can cause a high proportion
of false positive diagnoses. Although this strategy is known
to be inferior to providing patients with an inconclusive
status and requesting them to retest in 14 days, many
programmes continue to use a tiebreaker out of conve-
nience, the desire to make an immediate diagnosis so that
ART can be initiated and concerns that clients will be lost
to follow-up [22].
User and clerical errors at testing sites are also a factor as
reported by Khan et al. in this issue [23]. In their study, nearly
all of the misdiagnosed patients unnecessarily placed on ART
reported that they had at least one HIV-negative test result
before they were started on treatment; additionally, two
other patients reported that they were never shown their
test results despite being given an HIV-positive diagnosis.
Authors suggest these cases of misdiagnosis were likely due
to administrative error, user error and clients’ circumstantial
belief that they were HIV positive [23]. Thus, it is likely that
these cases of misdiagnosis could have been prevented if
health workers had a clear understanding of how to commu-
nicate uncertainty of test results and if procedures for addres-
sing potential misdiagnoses were in place.
Other reported factors, related specifically to false nega-
tive diagnoses, included early/acute HIV infection [24] and
testing among people on ART (e.g. people who retest
without disclosing their ART use) [18]. According to Kufa
et al., false negative diagnoses were associated with a
reactive HIV-1 Limiting Antigen enzyme immunoassay
(LAg EIA) test result (i.e. a marker of early/acute infec-
tion), individuals reporting an HIV-positive status and
those reporting ART use [24]. Patients on ART who retest
may have low levels of detectable HIV antibodies. Two
reports in this issue found that 8.5–44% of false negative
diagnoses were among people on ART who were retested
[21,25]. According to Olaru et al. [25], which sought to
investigate the impact of ART on test performance, 8.5%
of children with HIV on ART had a false negative test
result when using an oral fluid-based rapid diagnostic
test (RDT), and those who had been on ART longer and
who had higher CD4 counts were more likely to have a
negative test.
Understanding the factors contributing to misdiagnosis
across specific contexts is critical to developing a public
health approach that will be effective in both addressing
and preventing misdiagnosis in the scale-up of HIV rapid
testing programmes.
What are the consequences and costs of
misdiagnosis?
The importance, and possible consequences, of misdiagno-
sis should not be underestimated. On an individual level,
false positive diagnoses can lead to unnecessary financial
expenses, clinical visits and treatment initiation causing
physical, emotional and psychosocial harm [12,23,26].
According to an MSF study, many of those misdiagnosed
were not identified and re-diagnosed as HIV negative for at
least a year during which 10 people were placed on ART: six
for treatment, and four (two mother–baby pairs) to prevent
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Figure 1. HIV testing continuum and the patient, provider, facility and system-level dimensions of where diagnostic errors and HIV
misdiagnosis can occur [20].
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vertical transmission [12]. While the majority of those mis-
diagnosed were pleased to learn they were HIV negative,
several were reportedly overwhelmed by the news as their
HIV-positive diagnosis had disrupted their lives through
stigma, broken relationships and divorce [12]. Additionally,
missed opportunities to diagnose HIV due to false negative
results continues to cause delays in the initiation of life-
saving treatment and contributes to both on-going HIV
transmission and HIV-related morbidity in adults, and as
reported by Technau et al. in this issue, amongst HIV-
exposed infants with inconclusive results [27].
The potential financial and economic cost of false mis-
diagnoses is likely to be high. False positive diagnoses, as
reported in South Africa by Hsiao and colleagues in this
issue [28], lead to unnecessary ART costs, even with ≤1%
misdiagnoses. Mathematical modelling suggests pro-
grammes which do not retest people with an HIV positive
diagnosis prior to initiating treatment could spend between
US$58,000 and US$225,000 in unnecessary ART costs per
year for both low (1%) and high (10%) HIV prevalence
settings [29]. Since there is currently no available HIV test-
ing technology validated for testing people on ART, alter-
native strategies to determine a patient’s true HIV status
after they start treatment require the testing of viral reser-
voirs [30–32]. These strategies are not only complex, unfea-
sible in many settings and costly, but ill-advised as they
could be potentially harmful to patients. Additionally, as
many patients are now offered treatment immediately
after diagnosis, the occurrence of seroreversion among
patients on treatment may become more common, espe-
cially among infants and children [25]. Understanding the
implications and the best practices to address retesting
among people on ART, as well as the potential implications
for retesting people on pre-exposure prophylaxis, is an area
needing further research that can guide the implementa-
tion of practical solutions.
From a public health perspective, misdiagnoses in the
context of HIV surveillance may result in under- or over-
estimations of HIV prevalence and may have particular
implications when programme data from RDT are used
[33,34]. False negative diagnoses could also lead to
further HIV transmission by providing a false sense of
security. As many as 70% of new HIV transmissions may
be attributable to undiagnosed HIV infection [35], with
early/acute infection contributing to 10–50% of new HIV
transmissions [36]. Furthermore, misdiagnoses may also
undermine public trust in test results as well as trust in
health services. Such distrust can be detrimental, as it can
be a barrier preventing and delaying individuals from
accessing services [37], potentially exacerbating gaps in
HIV testing, prevention and treatment coverage.
Are there additional challenges to addressing
misdiagnosis in infants and children?
Sacks et al. [38] note a number of key differences affecting
the interpretation and management of test results in
infants and children such as vertical transmission dynamics
and the natural history and decay of maternal antibodies.
The consequences of delayed, false negative and false
positive diagnoses, while serious for all ages, are more so
for children. Inconclusive results delayed delivery of a final
HIV-positive diagnosis; and 17% of infants with HIV with an
inconclusive diagnosis died [27]. Olaru et al. note that some
children who start ART early in life never develop HIV
antibodies to establish a definitive HIV diagnosis [25], mak-
ing cases where HIV-negative infants are unnecessarily
placed on treatment even more challenging to resolve
[38]. With these challenges in mind, in order to address
and minimize misdiagnosis in infants and children, it is an
urgent priority to retain all HIV-exposed infants and chil-
dren with HIV-negative or inconclusive test results in care
until a final diagnosis is ascertained after completion of
breastfeeding and for testing to verify the HIV status of
any child who has an initial nucleic acid test with detectable
results immediately [38].
How should HIV misdiagnosis be prevented and
addressed?
A combination of policy and programmatic approaches will
be needed to address and prevent misdiagnoses. As out-
lined by Singh and Sittig in the “Safer Dx framework”
(Figure 2) [39], preventing error and misdiagnosis will
require a variety of stakeholders including researchers,
health workers, policymakers, programme managers, imple-
menting partners, civil society and patient advocates to
develop and implement strategies and tools for measuring
and monitoring diagnostic error, as well as to provide feed-
back and learning to inform the implementation of inter-
ventions that minimize misdiagnoses, improve testing
quality and result in improved patient outcomes.
First, ensuring that appropriate and quality-assured tests
are selected and procured based on a proven testing strategy
and validated testing algorithm is critical. A 2015 policy review
suggested that fewer than 20% of national HIV testing strate-
gies were in line with WHO recommendations [40]. Revising
these strategies to ensure that a sensitive first-line assay and
referral of discrepant results for retesting at 14 days are used
instead of using a tiebreaker will have a significant impact.
Conducting or utilizing findings from testing algorithm valida-
tion studies is a key way programmes can reduce the risk of
misdiagnosis. Although additional resources may be needed
to validate algorithms and replace the use of a tiebreaker test
with active follow-up and testing of patients with inconclusive
results, this is likely to be a better investment than continuing
to deliver potentially incorrect test results which may lead to
the unnecessary ART initiation.
Second, retesting prior to ART initiation should be imple-
mented as a routine service and considered the standard of
care [17,41]. Despite some concerns about potential costs
and feasibility, it is cost-effective [28,29], and can improve
testing quality and reduce misdiagnosis. Programmatic
reports from Malawi show that since implementing retest-
ing prior to ART, together with retraining testers and intro-
ducing new guidelines on supervision, the proportion of
patients misdiagnosed has decreased from approximately
7% in 2014 to 1% in 2016 [42].
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Third, quality assurance systems are essential to HIV
testing services. Training, support and supervision are key
for all HIV testing providers, as well as routine external
quality assessment schemes which help identify where pro-
blems may be occurring and which HIV testing providers
and sites might benefit most from additional training and
support. Standardized testing registers and logbooks
improve reporting systems and, when maintained, can
help programmes quickly identify and assess emerging
quality issues and take corrective action. Electronic record
systems can accelerate the identification of errors and mis-
diagnoses by quickly gathering and assessing patient-level
information and tracking and following-up of those with
characteristics linked to misdiagnosis [43]. The assignment
of a unique patient identifier so that all of the testing
results for the one client can be followed and evaluated
over time is critical to identifying potential misdiagnosis.
Many of the studies included in this special issue are
examples of how investigating quality issues can lead to
improvements in testing services and how combining qual-
ity assurance systems with scale-up can mean that increas-
ing quantity does not necessarily compromise quality.
Nguyen and colleagues [44] were able to simultaneously
scale-up HIV testing for key populations through commu-
nity-based services and also prevent misdiagnosis by using
a valid testing algorithm and quality assessment tools and
systems. Bock and colleagues demonstrate that through
assessing testing quality and identifying serious testing
issues, by following up and implementing retraining, addi-
tional supervision, the use of a second reader for RDT
results and retesting prior to ART, testing quality improved
and errors became infrequent [21].
Can we have quantity and quality?
Correct HIV test results are one of the WHO “5Cs” and a
guiding principle to the delivery of HIV testing services
worldwide. Achieving the UN 90-90-90 targets is key to
the global public health agenda; however, achieving these
goals while also meeting quality testing standards has pro-
ven difficult. Continued expansion of HIV testing services
and treatment has tremendous individual and public health
benefits, but must include accurate diagnosis. Now that
ART will be offered to all people with HIV immediately
after diagnosis, preventing and addressing misdiagnosis is
of paramount importance. Every effort to prevent and
address misdiagnosis if and when it occurs must be made
alongside the scale-up of HIV testing services.
Communicating and coping with uncertainty in any
health-related test results is difficult for healthcare provi-
ders and patients alike. On occasion, it may not be possi-
ble to deliver an HIV diagnosis on the same day, and
further testing after a period of time will be needed.
This message must be understood and conveyed by test-
ing providers to their clients. Developing community mes-
saging around the limitations of testing in certain contexts,
despite their high accuracy and reliability, may be bene-
ficial. In particular, messaging around the possibility that
some clients may not be able to receive a same day
diagnosis and returning for test results will be needed.
Furthermore, although uncertainties may occur, misdiag-
noses are mostly preventable through quality systems,
appropriate algorithm use, retesting prior to ART initia-
tion and follow-up procedures to correct discrepancies
should they arise.
Current research demonstrating the benefits of
immediate ART, for the individual and to prevent trans-
mission, has led activists, national governments, interna-
tional donors and the non-governmental community to
fund and implement unprecedented efforts to provide
treatment for everyone with HIV. We now need the
same level of activism and global commitment to insist
on accuracy of HIV testing.
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Figure 2. Safer Dx framework, adapted from Singh and Sittig 2015 [39].
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